Immune responses and viral persistence in SHIV.C.CH848-infected rhesus macaques

Widade Ziani1#, Anya Bauer2#, Hong Lu3, Xiaolei Wang1, Xueling Wu3, Katharine J. Bar2, Hui Li2, Dongfang Liu4, George M. Shaw2, Ronald S. Veazey1 and Huanbin Xu1*

1 Tulane National Primate Research Center, Tulane University School of Medicine, Covington, Louisiana, USA
2 Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
3 Aaron Diamond AIDS Research Center, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA
4 Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School, Newark, New Jersey, USA

*Address correspondence to Huanbin Xu, Tulane National Primate Research Center, Division of Comparative Pathology, 18703 Three Rivers Road, Covington, LA 70433, USA; Phone: (985) 871-6401; Fax: (985) 871-6510; Email: hxu@tulane.edu

# Widade Ziani and Anya Bauer are co-first authors. Author order was determined by contributions.

Running head: SHIV.C.CH848 infection in RMs
Abstract

Chimeric simian/human immunodeficiency viruses (SHIVs) are widely used in nonhuman primate models to recapitulate HIV infection in humans, yet most SHIVs fail to establish persistent viral infection. We investigated immunological and virological events in rhesus macaques infected with the newly developed SHIV.C.CH848, combined with antiretroviral therapy (cART). Similar to HIV/SIV infection, SHIV.C.CH848 infection established viral reservoirs in CD4+ T cells and myeloid cells, accompanied by productive infection and depletion of CD4+ T cells in systemic and lymphoid tissues throughout SHIV infection. Despite 6-months of cART suppressed viral replication, integrated proviral DNA levels remained stable, especially in CD4+ T cells, and the viral rebound was also observed after ART interruption. Autologous neutralizing antibodies to the parental HIV-1 strain CH848 were detected, with limited viral evolution at 5 months post infection. In comparison, heterogenous neutralizing antibodies in SHIV.C.CH848-infected macaques were not detected except for one (1 of 10) animal at 2 years post infection. These findings suggest that the SHIV.C.CH848, a novel class of transmitted/founder SHIVs, can establish sustained viremia and viral reservoirs in rhesus macaques with clinical immunodeficiency consequences, providing a valuable SHIV model for HIV research.

Importance

SHIVs have been extensively used in a nonhuman primate (NHP) model for HIV research. Here, we investigate viral reservoir in tissues and immune responses in an NHP model inoculated with newly generated transmitted/founder HIV-1 clade C-based SHIV.C.CH848. The data show T/F SHIVC infection of macaques more closely recapitulates the virologic and clinical features of HIV infection including persistent viremia, and viral rebound once antiretroviral therapy is discontinued. These results suggest this CCR5-tropic, SHIVC virus is valuable for testing responses to HIV vaccines and therapeutics.

Keywords: SHIV, persistent infection, viral reservoirs, autologous neutralizing Abs and evolution
Introduction

Chimeric simian/human immunodeficiency viruses (SHIVs), carrying HIV envelope glycoproteins from transmitted founder (T/F) viruses, are invaluable for testing HIV transmission, pathogenesis, and prevention strategies in nonhuman primate models (1-5). However, the majority of current SHIVs have limitations including differences in co-receptor usage, and a lack of sustained viremia or progression to AIDS (5-11). Therefore, the development of functional SHIV clones that better mimic the natural history of HIV infection and that reflect co-receptor usage of globally circulating T/F viruses resulting in establishment of persistent viral reservoirs in animal models is of great significance for testing HIV prevention and cure strategies.

Clade C viruses represent the predominant HIV subtype in the global HIV pandemic, yet most SHIVs to date have been either derived from clade B (SHIVsf262P, SHIVAD8) or utilize different co-receptors from that of HIV T/F strains (SHIV89.6P, SHIV KU, etc.), which exclusively utilize CCR5. The new CCR5-tropic clade C SHIV (SHIV.C.CH848) clone (12-14) encodes for a clade C Env isolated from an acutely-infected Malawian man in 2008 (15), and was developed by a single amino acid substitution at Env residue 375 to increase the affinity of CH848 Env for rhesus CD4 (16, 17). Here, we investigate immunological and virological events in SHIV.C.CH848-infected animals in acute infection and on antiretroviral therapy including CD4+ T cells, neutralizing antibody responses, and Env viral evolution. SHIV.C.CH848 infection resulted in acute depletion of peripheral CD4+ T cells and persistent viral infection, as indicated by detectable proviral DNA even after 6-months of cART treatment, and viral rebound after cART interruption. A potent autologous (but not heterogenous) neutralizing antibody response was detected from 5 months to 2 years post infection (p.i.). These findings suggest this novel T/F SHIV.C.CH848 is a promising model for HIV latency and cure studies.

Materials and Methods

Ethics statement

All animals in this study were housed at the Tulane National Primate Research Center in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care International standards. All studies were reviewed and approved by the Tulane University Institutional Animal Care and Use Committee.
under protocol number P0305R. Animal housing and studies were carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health (NIH, AAALAC #000594) and with the recommendations of the Weatherall report on "The use of nonhuman primates in research". All clinical procedures were carried out under the direction of a laboratory animal veterinarian. All procedures were performed under anesthesia using ketamine, and all efforts were made to minimize stress, improve housing conditions, and to provide enrichment opportunities (e.g., objects to manipulate in cage, varied food supplements, foraging and task-oriented feeding methods, interaction with caregivers and research staff).

**Animals and virus**

A total of 10 adult Indian-origin rhesus macaques (Macaca mulatta; RMs) were intravenously inoculated with 1,000 TCID50 SHIV.C.CH848 (1:10 diluted stocks containing 4.4 \( \times 10^6 \) infectious units as determined by TZM-bl cells), in which SHIV.C.CH848.375H.dCT was constructed and generated as described (16). After 20 weeks, 5 animals received combined anti-viral drugs (Tenofovir-TFV 20 mg/kg/day; Emtricitabine-FTC 30 mg/kg/day and Dolutegravir-DTG at 2.5 mg/kg/day) for 6 months. Tenofovir-TFV and Emtricitabine-FTC were kindly provided by Gilead Inc., and Dolutegravir-DTG was kindly provided by ViiV Healthcare. Blood, lymph node, and rectal biopsies were collected at the time scheduled, processed into single-cell suspensions, analyzed by flow cytometry, and examined by quantitative cell-associated viral DNA/RNA analysis.

**Cells and plasmids**

The TZM-bl cells and the HIV-1 SG3\(\Delta\)env backbone were obtained from the NIH AIDS Reagent Program (18, 19). The HIV-1 clade A, B, and C reference rev-env expression plasmids were obtained from the NIH AIDS Reagent Program (20-23). HIV-1 Env pseudoviruses were generated by co-transfecting 293T clone 17 (ATCC, Manassas, VA) with Env plasmids, including the parental HIV-1 clade C CH848 rev-env expression plasmid, along with the SG3\(\Delta\)env backbone.

**Tissue collection and phenotyping**

Flow cytometry for surface and intracellular staining was performed using standard protocols (24). Cells were stained with: CD3 (SP34), CD4 (OKT4, BioLegend), CD8 (SK1), CD20 (2H7), and LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Grand Island, NY). Isotype-matched controls were included in all
experiments. All antibodies and reagents were purchased from BD Biosciences Pharmingen (San Diego, CA) unless otherwise noted. Samples were resuspended in BD Stabilizing Fixative (BD Biosciences) and acquired on a FACS FORTESSA (Becton Dickinson). Data were analyzed with FlowJo software (Tree Star, Ashland, OR).

Measurement of gag-specific CD8+ T cells in blood

SHIV gag-specific CD8+ T cells were detected as we previously described (25). In brief, PBMCs were stimulated by a pool of 15-mer Gag peptides (5 μg/ml each peptide), medium (negative control), or phorbol-12-myristate-13-acetate (PMA, 5ng/ml, Sigma) plus ionomycin (50μg/ml) (positive control) for 6h. The cultures also contained brefeldin A (Sigma) and 1 μg/ml of anti-CD49d and anti-CD28 co-stimulatory molecules (BD Biosciences). Cultured cells were stained with monoclonal antibodies specific for surface molecules (CD3, CD4, CD8 and Live/Dead cell staining kit). After fixation and permeabilization with Cytofix/Cytoperm solution (BD Biosciences), cells were further stained with antibodies specific for IFN-γ (clone 4S.B3), and TNF-α (clone MAB11) and washed by Perm/wash buffer (BD Biosciences). Finally, labeled cells were fixed in 1.5% paraformaldehyde, acquired with a FACSA Verse cytometer (Becton Dickinson, San Jose, CA), and data analyzed using FlowJo software (Tree Star, Ashland, OR). The background level of cytokine staining varied within different samples and different cytokine patterns but was typically <0.05% of total CD8+ T cells (median, 0.01%). Only samples in which the percentage of cytokine-staining cells was at least twice that of background were considered positive.

Purification of CD4+ T cell subsets

Fresh PBMCs or LNMCs were incubated with anti-CD4 microbeads (Miltenyi) for 30 min, washed, and resuspended in MACS buffer to purify CD4+ T cells following the manufacturer’s instruction.

Genomic DNA and total RNA extraction

Fresh single cell suspensions isolated from EDTA-treated venous blood by density gradient centrifugation with Lymphocyte Separation Medium (MP Biomedicals, Santa Ana, CA) and lymph nodes at different time points were processed to extract total genomic DNA and cellular RNA using the AllPrep DNA/RNA Mini Kit (Qiagen) according to the manufacturer’s instructions. Viral RNA in plasma was directly isolated using the QIAamp Viral RNA Mini Kit (Qiagen). The extracted cellular DNA and RNA samples were stored at -80°C for...
Quantification of plasma viral load and cell-associated SHIV RNA

The extracted RNA was reverse transcribed into cDNA using a SuperScript III first-strand synthesis system (Invitrogen) according to the manufacturer’s protocol. RT reactions were performed in a thermocycler at 25°C for 5 min, 50°C for 60 min, followed by an enzyme inactivation step at 70°C for 15 min. For quantification of targets, all primer/probe sets were synthesized by Integrated DNA Technologies IDT (Coralville, IA, USA) to target the SIVmac239 gag region (Forward primer: GTC TGC GTC ATC TGG TGC ATT C; Reverse primer: CAC TAG GTG TCT CTG CAC TAT CTG TTT TG; and probe: FAM-CTT CCT CAG TGT GTT TCA TCT TCT TCT CCG -BHQ-1). Plasma viral loads were measured by real-time PCR as we previously described (26). cDNA from cell-derived RNA was used to quantify unspliced RNA transcripts by digital droplet PCR (QX100 Droplet Digital qPCR system, Bio-Rad) as our recently described (27). Samples were run in duplicate in a 20μL volume containing Supermix, 250nM primers, 900nM probe, and 2μL undiluted cDNA as following cycling conditions: 10 min at 95°C, 40 cycles of 94°C/30s and 63°C/60s, followed by final 98°C for 10 min. Droplets were analyzed by the QuantaSoft software in the absolute quantification mode. Copies of SIV transcripts expressed as copies per one million cells were measured and normalized to cellular input, as determined by copies of genomic CCR5 (single-copy rhesus macaque CCR5 DNA per cell) (28-32). The limit of detection (LOD) was based on three or more replicates and calculated using GenEx 5 (www.multid.se).

Quantification of cell-associated SHIV DNA

To ensure that quantification of total SHIV DNA and proviral DNA is comparable, a series of specific standards (plasmids containing SIV U5 DNA or CCR5 DNA fragment) were prepared to perform nested PCR. Since HIV preferentially integrates into regions of the chromosome close to Alu repeats, two Alu primers were used to amplify the segments of integrated proviral DNA (33). Two-step PCR amplification was run in parallel to quantify viral DNA as described (27). Briefly, the preamplification reactions were performed using SIV long terminal repeat primer and two outward Alu primers, or primer pairs of U5 (Forward primer: AGG CTG GCA GAT TGA GCC CTG GGA GGT TC; Reverse primer: CCA GGC GGC GAC TAG GAG AGA TGG GAA CAC; probe: FAM-TTC CCT GCT AGA CTC TCA CCA GCA CTT GG-BHQ-1) on 7900HT Sequence Detectors (Life
Technologies). The reaction conditions were performed as following: 25μL of the reaction mix, containing 1X PCR buffer, 0.2mM dNTPs, 2mM MgCl₂, 0.8μM of each primer, and 0.5U Taq DNA polymerase (Invitrogen Life Technologies), was programmed to perform a 5 minutes hot start at 95°C, followed by 20 cycles of denaturation at 95°C for 30 seconds, annealing at 63°C for 30 seconds and extension at 72°C for 3 minutes. 2.5μL of these amplicons were further amplified in triplicate with each primer/probe pairs by real-time PCR reaction using 40 cycles at 95°C for 15 seconds and 63°C for 1 minute. The highly reproducible calibration curves were generated by plotting Cq values against log-transformed concentrations of serial standard. Internal standard curves were also generated using the known copy number of target plasmids (1-500 copies) diluted in cellular DNA from SIV naïve RMs. The calibration curves and the internal regression curves were used for interpolating initial copies of each target in unknown samples. A non-template control (NTC) and extracted cellular DNA from the HUT78/SIVmac239 cell line (positive control) were included in the qPCR reactions. As described above, quantification of SHIV RNA/DNA was expressed as copies per 1 million cells, in which cell numbers were determined by copies of genomic CCR5 DNA per cell.

**Antibody neutralization assays**

TZM-bl neutralization assays were performed using single-round infection of TZM-bl cells with Env pseudoviruses as described (16, 34-36). For each of the 10 SHIV.C.CH848 infected rhesus macaques, plasma neutralization was tested at 3 time points: 5 months, 15 months, and 2 years post infection. Briefly, TZM-bl cells were seeded at 10,000 cells per well. After 24 hours, plasma was serially diluted 5-fold, starting at a dilution of 1:20 and incubated with 4,000 IU of virus stock as measured via titration on TZM-bl cells. The sham medium was used in place of plasma in specified control wells. The autologous infectious molecular SHIV clone, SHIV.C.CH848, and the pseudotyped HIV-1 CH848, were used to assess the neutralizing antibody titers. Pseudotyped MLV was used as a negative control. Antibody-virus mixtures were co-incubated for 1 h and then added in triplicate to pre-seeded TZM-bl cells. After 48 hours, cells were simultaneously lysed and mixed with luciferase substrate via the addition of Bright-Glo (Promega). Background-corrected luciferase activity for each sample was determined. Neutralization curves were fitted by the 5-parameter nonlinear regression built in Prism 8.0. The 50% inhibitory dilutions (ID50) values were determined by the plasma reciprocal dilutions required to inhibit viral infection by 50%.
**Viral sequencing**

Single-genome full-length gp160 env sequences were generated as described (16). Briefly, up to 20,000 viral RNA copies were extracted from 400 μl of plasma virus from 5 months post-infection using the Qiagen BioRobot EZ1 Workstation with EZ1 Virus Mini Kit v2.0 (Qiagen). Eluted vRNA was subsequently used as a template for cDNA synthesis and reverse-transcribed using the reverse primer SHIV.Env.R1 (5’-TAC CCC TAC CAA GTC ATC A-3’) and SuperScript III reverse transcriptase (Invitrogen Life Technologies). cDNA was serially diluted in a 96-well plate (Applied Biosystems) to identify the dilution at which <30% of wells contained PCR amplicons of the correct size. The SHIV gp160 env genome was amplified via nested PCR with primers as follows: first-round forward primer SHIV.Env.F1 (5’-CGA ATG GCT AAA CAG AAC A-3’), second-round forward primer SHIV.Env.F2 (CTA CCA AGG GAG CTG ATT TTC), first-round reverse primer SHIV.Env.R1 (5’-TAC CCC TAC CAA GTC ATC A-3’), and second-round reverse primer SHIV.Env.R2 5’-TAT TTT GTT TTC TGT ATGCT-3’). PCR conditions were used as follows for the first round of nested PCR: 94°C, 2 min; 37x [94°C, 20 sec; 55°C, 30 sec; 68°C, 3 min 30 sec]; 68°C, 10 min. For the second round of nested PCR, the PCR conditions were as follows: 94°C, 2 min; 42x [94°C, 20 sec; 54°C, 30 sec; 68°C, 3 min 30 sec]; 68°C, 10 min. Amplicons were sequenced via the MiSeq platform (Illumina). Raw reads were aligned to the SHIV.C.CH848 TF reference using Geneious R9. Sequences that contained mixed bases at a frequency of >25% per nucleotide position were excluded from further analysis. Single genome sequences were not able to be generated for 3 of 10 rhesus macaques, likely due to a sample storage issue.

**Statistics**

Statistical analyses were performed by GraphPad Prism 7.0 Software (GraphPad). Nonparametric tests were used for all statistical comparisons within animal tissues under cART. The Mann-Whitney test was used to test for differences in set point viral loads, cell-associated SHIV RNA/DNA, and specific cell subsets in animals before and after cART. Significant statistic differences are indicated by asterisks (*p<0.05). The data are presented as mean and SEM.

**Results**
Plasma viral load and immunological responses in SHIV.C.CH848-infected rhesus macaques on antiretroviral therapy

Ten rhesus macaques were intravenously inoculated with SHIC.C.CH848, and half of the animals received anti-HIV drugs 5 months post infection. As indicated in Figs. 1a and 1b, plasma viral load peaked 14 days post SHIV infection, followed by a relatively sustained viral set point. Once cART was initiated (5 months post infection), viremia in treated animals (n=5) rapidly declined to be undetectable levels after two weeks, compared with untreated controls (n=5) that in a large part maintained the set point viral load. Notably, viral rebound was detected in 4/5 of the animals after cART interruption, except for one animal who remained aviremic up to 6 months after cART cessation. Further, SHIVC infection resulted in significant depletion of peripheral CD4+ T cells by 14 days post infection, and progressive reductions of rectal CD4+ T cells while peripheral CD20+ B cells and GC Tfh cells (PD-1high CXCR5+ cells gated CD4+ T cells) expanded in untreated animals by 5 months post infection. In contrast, cART treated animals significantly recovered CD4+ T cells in blood and rectum while maintaining baseline levels of peripheral CD20+ B cells and GC Tfh cells (Figs. 1c-1f). Since PD-1 upregulation reflects CD8+ T cell exhaustion during viral infection (37, 38), we examined PD-1 expression on peripheral CD8+ T cells throughout SHIVC infection. Results showed SHIVC infection significantly upregulated PD-1 on CD8+ T cells in untreated macaques, whereas reduced frequencies of PD-1+CD8+ T cells were detected in cART treated animals (Fig. 1g), consistent with lower SIV Gag-specific CTL responses in untreated animals at 44 weeks post infection (Fig. 1h). These data demonstrate that SHIV.C.CH848 recapitulates key virologic and immunologic characteristics of HIV-1 infection.

Viral dissemination in systemic and lymphoid compartments of SHIV CH848-infected rhesus macaques on antiretroviral therapy

To evaluate the dynamics of cell-associated SHIVC RNA/DNA in systemic and lymphoid tissues after SHIVC infection and their response to cART, unspliced (US) SHIVC RNA, total SHIV DNA, and proviral DNA were longitudinally measured in blood, lymph node, and rectal biopsies in SHIVC-infected macaques. As CD4+ T cells are preferentially targeted in HIV infection, CD4+ T cells were also purified from blood and lymph nodes to further assess cell-associated SHIV RNA/DNA levels, compared with the remaining CD4 negative cell populations. As shown in Fig. 2, both SHIV RNA and DNA were detected in both CD4+ and CD4 negative cell
populations in PBMCs and lymph node-derived mononuclear cells. Antiretroviral therapy suppressed SHIVC replication in both cell populations in blood and lymph nodes compared with untreated controls. Levels of US SHIVC RNA decreased to undetectable levels in both cell populations by 3 months of cART treatment, although LN-derived CD4+ T cells still had detectable viral RNA at this time point. At one months of cART interruption, US SHIVC RNA increased in both cell populations (Figs. 2a and 2b). Similarly, cART also reduced levels of total SHIVC DNA and proviral DNA in both CD4+ and negative cell populations within 3 months treatment (Figs. 2c-2f). However, total and proviral DNA were still detectable in CD4+ T cells throughout SHIVC infection, regardless of treatment duration. Notably, there was no significant reduction of proviral DNA levels in LN-derived CD4+ T cells in treated animals. However, there was no detectable proviral DNA in the corresponding CD4 negative cells after treatment (Figs. 2e and 2f). These data show that CD4+ T cells are the major reservoir for SHIV.C.CH848 persistence, especially in organized lymphoid tissues (LN), mimicking the hallmark qualities of HIV infection in humans.

Cell-associated SHIV RNA/DNA was also measured from rectal lymphocytes in SHIV.C.CH848-infected macaques, with or without cART. As shown in Figs. 3a-3c, the dynamics of rectal lymphocyte-associated SHIV RNA/DNA were very similar to those in blood and LN-derived CD4+ T cells, and cART did not significantly reduce levels of rectal cell-associated proviral DNA. Cell-associated viral nucleic acids were compared prior to treatment (5 months post infection) and after 6 months of cART (Figs. 3d-3f). Combined, these results showed that changes in SIV RNA/DNA were similar in lymphocytes from blood, LNs and rectum and that SHIV.C.CH848 infection results in viral persistence and stable, latent viral reservoirs in both systemic and lymphoid tissue compartments on treatment, that result in viral resurgence after treatment withdrawal.

Plasma neutralizing antibody responses in SHIV.C.CH848-infected macaques

We next performed TZM-bl neutralization assays to characterize neutralizing antibody responses in these macaques at 5, 15, and 24 months post infection (Table 1). These animals developed autologous neutralizing antibody against SHIV.C.CH848 with variable potency (ID50 titers ranged from less than 1:50 to more than 1:300) at 5 months post infection, consistent with previous reports that autologous neutralizing antibody responses are common and arise relatively early in viremic macaques in the first few weeks to months post-infection (9, 39-41). At 2 years post infection, regardless cART, the plasma neutralization titers
against SHIV.C.CH848 increased in 6 of 9 macaques (animal #9 died before this time point), exhibiting neutralization ID50 titers of ≥1:300 dilution.

In contrast, none of the animals developed heterogenous neutralizing antibodies against the seven heterologous HIV-1 strains tested across clades A, B, and C at 15 months post infection. At 2 years post infection, there were no appreciable cross-reactive neutralizing antibodies in the 6 animals with CH848 ID50 ≥1:300, except for animal #7, in which the plasma cross-neutralized the clade A strain Q23.17 with an ID50 of ~1:300 and weakly neutralized the clade C strain ZM109.4 with an ID50 of ~1:50 dilution (Table 1). In summary, 9 out of 10 SHIV.C.CH848 infected macaques mounted potent autologous neutralization antibody responses against the CH848 Env, whereas there were limited heterologous antibodies elicited in one infected animal.

**Viral diversity in SHIV.C.CH848-infected macaques**

Single genome sequencing (SGS) of SHIV.C.CH848 gp160 env was used to characterize sequence diversity 5 months post-infection. A total of 31 sequences (median = 5 sequences per animal) were generated from 7 infected rhesus macaques. Sequences were aligned to the human CH848 T/F Env. As indicated in Fig. 4, 2 conserved sites of selection pressure were identified in Env: V3M or M4T/R mutations were detected in 3 of 7 macaques and the P195S/L mutation was detected in 4 of 7 macaques. Further, while sites of selection pressure across V1V2 were identified in all 7 animals, no mutations were conserved across the entire cohort. These results suggest that at 5 months post-infection, there was minimal sequence evolution in Env in this cohort of SHIV.C.CH848-infected rhesus macaques.

**Discussion**

SHIVs are widely used to explore HIV transmission, pathogenesis, latency, and cure strategies in NHP models of HIV/AIDS for over 20 years. Here, we characterized the key features of a novel T/F SHIV.C.CH848 infection in rhesus macaques on cART. Our results indicated that SHIV.C.CH848 infection leads to the recapitulation of key immunologic and virologic characteristics that are hallmarks of HIV-1 infection.

HIV infection establishes a long-lived latent reservoir extremely early after infection (42). However, combined antiretroviral therapy (cART) basically fails to eliminate HIV latency characterized by integrated
intact viral genomes, allowing the virus to persist for the lifetime of people living with HIV-1 (43-46). SHIV strains are very useful in the NHP models for testing antiviral drugs, HIV vaccines, and functional cure strategies especially if a small number of replication-competent viral reservoirs/latency are maintained. Although several SHIVs have been used in macaques (7, 47), their low viral persistence and often spontaneous clearance in macaques limit their potential for studying HIV latency in a NHP setting (6, 11). Recently developed CCR5-tropic SHIV.C.CH848 and CH505 strains, encoding Env from a transmitted founder HIV-1 subtype C, with an increased affinity for rhesus CD4 have shown promise for viral replication kinetics more closely resembling HIV infection in humans (16, 17, 48). Here we analyzed neutralizing antibody responses and cellular reservoirs in systemic and lymphoid tissues of rhesus macaques infected with T/F SHIV.C.CH848, before and after cART treatment and interruption. These data demonstrate that this novel T/F SHIV.C.CH848 virus is promising as a candidate for testing HIV treatment and cure strategies.

T/F SHIV.C.CH848 infection in rhesus macaques during early and chronic infection closely mirrors HIV infection, as indicated by high peak viremia in primary infection, relatively stable viral set point of $10^4 - 10^5$ viral RNA copies/ml plasma, massive gut-associated mucosal CD4+ T cell depletion, stable proviral DNA in systemic and lymphoid tissues even after 6-month cART and viral rebound after treatment interruption. Recrudescence of SHIVC is observed within 4 months of treatment interruption, consistent with the viral rebound that occurs in most HIV+ patients after ART interruption, ranging from ~5 days to 48 days (49, 50). However, viral rebound was not still observed in one animal at 6 months after ART cessation, compared with stable viremic set point in untreated animals. Unlike SIV-infected macaques that show rapidly viral rebound after analytic treatment interruption, some SHIV.C.CH848-infected animals showed a delayed viral recrudescence, which might be attribute to limited chronic activation and latency reactivation, as indicated by lower levels of plasma inflammatory cytokines and chemokines (e.g. IL-8 and MIP-1β) at 3 weeks after treatment discontinuation, compared with those at pre-treatment (data not shown). CCR5-tropic SHIV.C.CH848 efficiently infects rhesus macaques, resulting in persistent high levels of viremia, viral reservoir seeding and depletion of CD4+ T cells, consistent with SHIV AD8 infected macaques (8, 51, 52). However, circulating CD4+ T cells were rapidly restored in SHIV.C.CH848-infected macaques after ART was initiated. Given SIVmac-infected macaques show higher viremia, and contain higher proportions of intact viral genome (~84%, SIV vs. 11.7%, HIV) on ART (53-55), SHIV.C.CH848, equivalent to HIV, likely shows less pathogenicity
to SIVmac. In contrast to the depletion of CD4+ T cells, peripheral CD20+ B cells progressively increased throughout SHIV infection in untreated animals, yet cART prevented B-cell increases, suggesting that persistent SHIV infection leads to immune activation and B-cell hyperactivity if animals are untreated (56). To address the SHIV.C.CH848 latency, chronic activation and latency reactivation after treatment interruption, more animals are needed for these studies.

In the HIV/SIV life cycle, the virus produces unspliced RNA (~9 Kb), which is responsible for gag/pol translation and packaging of the viral RNA genome, representing *bona fide* viral replication (57, 58). Further, integrated proviral DNA is the reliable marker of persistent viral reservoirs with clinical relevance, especially in patients when plasma viremia is undetectable (46, 59-64). Since proviral DNA is a fundamental constituent of the latent reservoir, measurement of this in cells is a simple approach to estimate the persistent cellular reservoir that may fuel viral rebound, albeit this method cannot distinguish defective forms. Considering CD4+ T cells are primary targets and predominant cell reservoirs in HIV/SIV infection (65-67), purified CD4+ T cells and non-CD4+ cells were longitudinally compared for cell-associated viral RNA/DNA in blood and lymph nodes. Although levels of SHIV RNA/DNA were significantly different between CD4+ and CD4 negative cell populations, the latter including monocytes and other non-T and B cell subsets, the dynamics of viral RNA/DNA in two cell populations were similar, albeit CD4 negative cell populations showed at least one log lower levels of SHIV RNA/DNA.

Since non-CD4 cells can serve as reservoirs including monocytes, dendritic cells, and macrophages (68-73), CD14+ myeloid cells were also purified to compare levels of viral RNA/proviral DNA from chronically SHIV.C.CH848-infected macaques without treatment. As suspected, viral RNA/DNA levels in purified CD4+ T cells were much higher than in peripheral CD4-CD14+ myeloid cells (containing monocytes and macrophages) (viral RNA, 8.9×10e5 vs 6.8×10e4; proviral DNA, 5.8×10e3 vs 39.57), supporting the concept that CD4+ T cells are the major cellular reservoirs in HIV/SIV infection, but also that myeloid cells are an additional source of viral persistence (74). CD4+ T cells constitute the predominant reservoir in HIV infection, yet recent advances highlight the existence of HIV reservoir in tissue-resident myeloid cells (71, 72, 75-77). However, myeloid cells in blood and colon likely contain HIV transcripts but few proviruses in a large fraction of HIV+ patients, compared with CD4+ T cells with readily detectable proviral DNA (78, 79). Myeloid cells including monocytes
and macrophages are infected by HIV/SIV while circulating monocytes might not be considered reservoirs due to their infrequent HIV infection, low levels of proviral DNA and short life span (79). Macrophages likely represent long-lived myeloid reservoir for viral persistence, viral rebound and reestablishment of productive HIV infection when treatment is interrupted (80-86). Interestingly, the decay of both SHIV RNA and DNA in lymph nodes was slower than in blood under cART, consistent with the notion that lymphoid tissues may have suboptimal anti-HIV drug concentrations, and thus serve as sanctuary sites, resulting in viral persistence and viral resurgence after treatment is discontinued (26, 87-89). Importantly, cART did not significantly reduce levels of proviral DNA in blood, LNs and rectum, suggesting proviruses exist in multiple tissue sites, which may need to be addressed in HIV cure strategies. As ours and other studies report that GC Tfh cells are expanded and impaired in chronic SIV/HIV infection (90-92), LN-derived Tfh cells also increased in untreated SHIV.C.CH848-infected animals, yet decreased when cART was initiated.

People living with HIV often generate autologous neutralizing antibodies against transmitted/founder viruses within weeks to months post infection. Similarly, high levels of autologous neutralizing antibodies were observed against CH848 in 6 of 9 animals post infection (ID50 titers ≥1:300). Studies indicate that the appearance and persistence of neutralizing antibodies are mostly determined by the duration of HIV/SIV infection (93, 94), yet heterogenous neutralizing antibodies were essentially undetectable after 2 years of SHIV.C.CH848 infection. This is also consistent with previous reports and suggests that the quality of GC Tfh cells and subsequent maturation of antibody responses may be compromised (95, 96). GC Tfh cells represent a subsets of CD4+ T cells that mainly reside in the GC of follicles and involve iterative interaction with GC B cells in the GC reactions for neutralizing antibody generation (97). However, GC Tfh cell loss or functional impairment, in spite of accumulation of GC Tfh cell at chronic stage while serving as major source of the latent and productive viral reservoirs in persistent HIV/SIV infection, might be associated with defective Ab responses (26, 92, 98, 99). Further, virus evolution in HIV infected patients occurs concomitant with the emergence of selective pressures such as host CD8 T cell and antibody responses in the first weeks post infection (100, 101), as described in the report of the source patient infected with the CH848 T/F isolate, who developed first autologous and then heterologous V3-targeting antibodies (15). However, conserved sites of selection
pressure in V3 were not observed in any animal 5 months post-infection which may have been too early to
generate Env mutations in response to cell or neutralizing Ab responses.

In summary, here we characterized immunologic and virologic events in rhesus macaques infected with the
novel T/F SHIV.C.CH848, in combination with cART, and in response to treatment withdrawal. These findings
demonstrate that this novel T/F SHIV.C.CH848 virus has promising applications in NHP models to address
questions with regard to HIV reservoirs and persistence as well as relevant HIV vaccine and cure strategies.

Acknowledgments

We thank Meagan Watkins and Eunice Vincent for technical support.

This work was supported by NIH grants R01 DE025432, R01 AI147372, R01 HD099857, R01 Al099795, R01 AI114380, R01 AI122953, the National Center for Research Resources, and the Office of Research Infrastructure Programs (ORIP) of the National Institutes of Health through grant no. OD011104-51.

The funders had no role in study design, data collection and analysis, the decision to publish, or preparation of the manuscript.

WZ performed cell-associated virus measurement by qPCR and flow cytometry; AMB analyzed viral diversity; HL performed nAb assay; XW, XLW, KJB, DFL, GMS, RSV assisted with experiments, advice, and manuscript revision; HX. designed the study, analyzed the data and wrote the manuscript. The authors declare no competing financial interests.
References

1. Del Prete GQ, Lifson JD, Keele BF. 2016. Nonhuman primate models for the evaluation of HIV-1 preventive vaccine strategies: model parameter considerations and consequences. Curr Opin HIV AIDS 11:546-554.

2. Parsons MS, Le Grand R, Kent SJ. 2018. Neutralizing Antibody-Based Prevention of Cell-Associated HIV-1 Infection. Viruses 10.

3. Chen Z. 2018. Monkey Models and HIV Vaccine Research. Adv Exp Med Biol 1075:97-124.

4. Naranjo-Gomez M, Pelegrin M. 2019. Vaccinal effect of HIV-1 antibody therapy. Curr Opin HIV AIDS 14:325-333.

5. Horsburgh BA, Palmer S. 2019. For Viral Reservoir Studies, Timing Matters. Trends Microbiol 27:809-10.

6. Pahar B, Wang X, Dufour J, Lackner AA, Veazey RS. 2007. Virus-specific T cell responses in macaques acutely infected with SHIV(sf162p3). Virology 363:36-47.

7. Miller CJ, McChesney MB, Lu X, Dailey PJ, Chutkowski C, Lu D, Brosio P, Roberts B, Lu Y. 1997. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J Virol 71:1911-21.

8. Nishimura Y, Shingai M, Willey R, Sadjapour R, Lee WR, Brown CR, Brenchley JM, Buckler-White A, Petros R, Eckhaus M, Hoffman V, Igarashi T, Martin MA. 2010. Generation of the pathogenic R5-tropic simian/human immunodeficiency virus SHIVAD8 by serial passaging in rhesus macaques. J Virol 84:4769-81.

9. Shingai M, Donau OK, Schmidt SD, Gautam R, Plishka RJ, Buckler-White A, Sadjapour R, Lee WR, LaBranche CC, Montefiori DC, Mascola JR, Nishimura Y, Martin MA. 2012. Most rhesus macaques infected with the CCR5-tropic SHIV(AD8) generate cross-reactive antibodies that neutralize multiple HIV-1 strains. Proc Natl Acad Sci U S A 109:19769-74.

10. Mavignier M, Watkins B, Lawson B, Lee ST, Chahrroudi A, Kean L, Silvestri G. 2014. Persistence of Virus Reservoirs in ART-Treated SHIV-Infected Rhesus Macaques after Autologous Hematopoietic Stem Cell Transplant. PLoS Pathog 10:e1004406.

11. Garcia-Tellez T, Huot N, Ploquin MJ, Rascode P, Jacquelin B, Muller-Trutwin M. 2016. Non-human primates in HIV research: Achievements, limits and alternatives. Infect Genet Evol 46:324-332.

12. Bbosa N, Kaleebu P, Ssemwanga D. 2019. HIV subtype diversity worldwide. Curr Opin HIV AIDS 14:153-160.
13. Gartner MJ, Roche M, Churchill MJ, Gorry PR, Flynn JK. 2020. Understanding the mechanisms driving the spread of subtype C HIV-1. EBioMedicine 53:102682.

14. Tartaglia LJ, Gupte S, Pastores KC, Trott S, Abbink P, Mercado NB, Li Z, Liu PT, Borducchi EN, Chandrashekar A, Bondzie EA, Hamza V, Kordana N, Mahrokhian S, Lavine CL, Seaman MS, Li H, Shaw GM, Barouch DH. 2020. Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. J Virol 94.

15. Bonsignori M, Kreider EF, Fera D, Meyerhoff RR, Bradley T, Wiehe K, Alam SM, Aussedat B, Walkowicz WE, Hung KK, Saunders KO, Zhang R, Gladden MA, Monroe A, Kumar A, Xia SM, Cooper M, Louder MK, McKee K, Bailer RT, Pier BW, Jette CA, Kelsoe G, Williams WB, Morris L, Kappes J, Wagh K, Kamanga G, Cohen MS, Haber PT, Montefiori DC, Trama A, Liao HX, Kepler TB, Moody MA, Gao F, Danishefsky SJ, Mascola JR, Shaw GM, Hahn BH, Harrison SC, Korber BT, Haynes BF. 2017. Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci Transl Med 9.

16. Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, Kim E, Learn GH, Hahn P, Policicchio B, Brocca-Cofano E, Deleage C, Hao X, Chiang NY, Gorman J, Gardner M, Lewis MG, Hatziioannou T, Santra S, Apetrei C, Pandrea I, Alam SM, Liao HX, Shen X, Tomaras GD, Farzan M, Chertova E, Kenee BF, Estes JD, Lifson JD, Doms RW, Montefiori DC, Haynes BF, Sodroski JG, Kwong PD, Hahn BH, Shaw GM. 2016. Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A 113:E3413-22.

17. Bauer AM, Ziani W, Lindemuth E, Kuri-Cervantes L, Li H, Lee FH, Watkins M, Ding W, Xu H, Veazey R, Bar KJ. 2020. Novel Transmitted/Founder Simian-Human Immunodeficiency Viruses for Human Immunodeficiency Virus Latency and Cure Research. J Virol 94.

18. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46:1896-905.

19. Wei X, Decker JM, Wang S, Hui L, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. 2003. Antibody neutralization and escape by HIV-1. Nature 422:307-12.

20. Li M, Gao F, Mascola JR, Stamatas L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Biliska M, Kolhe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. 2005. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicted neutralizing antibodies. J Virol 79:10108-25.

21. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li Y, Salazar MG, Polonis VR, Misana K, Karim SA, Hong K, Greene KM, Biliska M, Zhou J, Allen S, Chomba E, Mulenga J, Wadika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori DC. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol 80:11776-90.

22. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J. 2002. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 18:567-76.

23. Blish CA, Jalalaini-Lechak Z, Rainwater S, Nguyen MA, Dogan OC, Overbaugh J. 2009. Cross-subtype neutralization sensitivity despite monoclonal antibody resistance among early subtype A, C, and D envelope variants of human immunodeficiency virus type 1. J Virol 83:7783-8.

24. Xu H, Wang X, Liu DX, Moroney-Rasmussen T, Lackner AA, Veazey RS. 2012. IL-17-producing innate lymphoid cells are restricted to mucosal tissues and are depleted in SIV-infected macaques. Mucosal Immunol 5:658-69.

25. Xu H, Wang X, Lackner AA, Veazey RS. 2013. CD8 down-regulation and functional impairment of SIV-specific cytotoxic T lymphocytes in lymphoid and mucosal tissues during SIV infection. J Leukoc Biol 93:943-50.

26. Xu H, Wang X, Malam N, Aye PP, Alvarez X, Lackner AA, Veazey RS. 2015. Persistent Simian Immunodeficiency Virus Infection Drives Differentiation, Aberrant Accumulation, and Latent Infection of Germinal Center Follicular T Helper Cells. J Virol 90:1578-87.
27. Ziani W, Shao J, Wang X, Russell-Lodrigue K, Liu YZ, Montaner LJ, Veazey RS, Xu H. 2021. Increased proviral DNA in circulating cells correlates with plasma viral rebound in SIV-infected rhesus macaques after antiretroviral therapy interruption. J Virol doi:10.1128/JVI.02064-20.

28. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M, Jr., Lifson JD, Picker LJ. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-7.

29. Okoye AA, Hansen SG, Vaidya M, Fukazawa Y, Park H, Duell DM, Lum R, Hughes CM, Ventura AB, Ainslie E, Ford JC, Morrow D, Gilbride RM, Legasse AW, Hesselgesser J, Geleziunas R, Li Y, Oswald K, Shoemaker R, Fast R, Bosche WJ, Borate BR, Edlefsen PT, Axthelm MK, Picker LJ, Lifson JD. 2018. Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat Med 24:1430-1440.

30. Hong F, Aga E, Cillo AR, Yates AL, Bessong G, Fyne E, Koontz DL, Jennings C, Zheng L, Mellors JW. 2016. Novel Assays for Measurement of Total Cell-Associated HIV-1 DNA and RNA. J Clin Microbiol 54:902-11.

31. Kostrikis LG, Touloumi G, Karanicolakos R, Pantazis N, Anastassopoulou C, Karafoulidou A, Goedert JJ, Hatzakis A, Multicenter Hemophilia Cohort Study G. 2002. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol 76:10999-108.

32. Deleage C, Immonen TT, Fennessy CM, Reynald R, Reid C, Newman L, Lipkey L, Schlub TE, Camus C, O'Brien S, Smedley J, Conway JM, Del Prete GQ, Davenport MP, Lifson JD, Estes JD, Keele BF. 2019. Defining early SIV replication and dissemination dynamics following vaginal transmission. Sci Adv 5:eaaav7116.

33. Cohn LB, ILT4, Oliveira TY, Rosales RA, Parrish EH, Lear NH, Hahn BH, Czartoski JL, McElrath MJ, Lehmann C, Klein F, Caskey M, Walker BD, Siliciano JD, Siliciano RF, Jankovic M, Nussenzweig MC. 2015. HIV-1 integration landscape during latent and active infection. Cell 160:420-32.

34. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, Coffey RT, Harris L, Lipkey L, Schlub TE, Camus C, Daniels MG, Bhattacharya T, Lapedes A, Polonis VR, McCutchan FE, Gilbert PB, Sel G, Korber BT, Montefiori DC, Mascola JR. 2010. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84:1439-52.

35. Wu X, Wang C, O'Dell S, Li Y, Keele BF, Yang Z, Imamichi H, Doria-Rose N, Hoxie JA, Connors M, Shaw GM, Wyatt RT, Mascola JR. 2012. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site. J Virol 86:5844-56.

36. Jia M, Lu H, Markowitz M, Cheng-Mayer C, Wu X. 2016. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques. J Virol 90:4017-31.

37. Xu H, Wang X, Pahar B, Moroney-Rasmussen T, Alvarez X, Lackner AA, Veazey RS. 2010. Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression. J Immunol 185:7340-8.

38. McLane LM, Abdel-Hakeem MS, Wherry EJ. 2019. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol 37:457-495.

39. Reynolds T. 1989. Noninvasive hemodynamic assessment of intracardiac pressures and assessment of ventricular function with cardiac Doppler. Crit Care Nurs Clin North Am 1:629-34.

40. Gao N, Wang W, Wang C, Gu T, Guo R, Yu B, Kong W, Qin C, Giorgi EE, Chen Z, Townsley S, Hu SL, Yu X, Gao F. 2018. Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection. AIDS 32:555-563.

41. Nelson AN, Goswami R, Dennis M, Tu J, Mangan RJ, Saha PT, Cain DW, Curtis AD, Shen X, Shaw GM, Bar K, Hodgins M, Pollara J, De Paris K, Van Rompuy KKA, Permar SR. 2019. Simian-Human Immunodeficiency Virus SHIV.CSIV05-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. J Virol 93.

42. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP.
2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med 15:893-900.

43. Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J, Blackmore S, Smith JY, Brinkman AL, Peter LE, Mathew SI, Smith KM, Borducchi EN, Rosenbloom DI, Lewis MG, Hattersley J, Li B, Hesseligasser J, Geleziamas R, Robb ML, Kim JH, Michael NL, Barouch DH. 2014. Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys. Nature doi:10.1038/nature13594.

44. Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, Khoruts A, Estes JD, Anderson J, Callisto SP, Schmidt ME, Thorkelson A, Reilly C, Perkey K, Reimann TG, Utay NS, Nganou Makamod K, Stevenson M, Douek DC, Haase AT, Schacker TW. 2015. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci U S A 112:E1126-34.

45. Kwon KJ, Siliciano RF. 2017. HIV persistence: clonal expansion of cells in the latent reservoir. J Clin Invest 127:2536-2538.

46. Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, Bogojeska J, Fellay J, Roth V, Kok YL, Thorball CW, Boghese A, Parbhoo S, Wieser M, Boni J, Perreau M, Klimkait T, Yerly S, Battegay M, Rauch A, Hoffmann M, Bernasconi E, Cavassini M, Koyouos RD, Gunthard HF, Metzner KJ, Swiss HIVCS. 2019. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART. Nat Commun 10:3193.

47. Jayaraman P, Mohan D, Polacino P, Kuller L, Sheikh N, Bielefeldt-Ohmann H, Richardson B, Anderson D, Hu SL, Haigwood NL. 2004. Perinatal transmission of SHIV-SF162P3 in Macaca nemestrina. J Med Primatol 33:243-50.

48. Bar KJ, Coronado E, Hensley-McBain T, O'Connor MA, Osborn JM, Miller C, Gott TM, Wangari S, Iwayama N, Ahrens CY, Smelley J, Moats C, Lynch RM, Haddad EK, Haigwood NL, Fuller DH, Shaw GM, Klett NR, Manuzak JA. 2019. Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology. J Virol 93.

49. Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, Rolland M, Takata H, Buranapraditkun S, Intasan J, Chomchey N, Muir R, Haddad EK, Toivanabutra S, Ubolyam S, Bolton DL, Fullmer BA, Gorelick RJ, Fox L, Crowell TA, Trichavarjor R, O'Connell R, Chomont N, Kim JH, Michael NL, Robb ML, Phanuphak N, Ananworanich J, group RVs. 2018. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat Med 24:923-926.

50. Ferris AL, Wells DW, Guo S, Del Prete GQ, Swanstrom AE, Coffin JM, Wu X, Lifson JD, Hughes SH. 2019. Clonal expansion of SIV-infected cells in macaques on antiretroviral therapy is similar to that of HIV-infected cells in humans. PLoS Pathog 15:e1007869.

51. Gautam R, Nishimura Y, Lee WR, Donau O, Buckler-White A, Shingai M, Sadjadpour R, Schmidt SD, LaBranche CC, Keele BF, Montefiori D, Mascola JR, Martin MA. 2012. Pathogenicity and mucosal transmissibility of the R5-tropic simian/human immunodeficiency virus SHIV(AD8) in rhesus macaques: implications for use in vaccine studies. J Virol 86:8516-26.

52. Martinez-Navio JM, Fuchs SP, Pantry SN, Lauer WA, Duggan NN, Keele BF, Rakasz EG, Gao G, Lifson JD, Desrosiers RC. 2019. Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies Can Drive Long-Term Virologic Suppression. Immunity 50:567-575 e5.

53. Vandergeetren C, Fromentin R, DaFonseca S, Lawani MB, Sereti I, Lederman MM, Ramgopal M, Routy JP, Sekaly RP, Chomont N. 2013. Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121:4321-9.

54. Pinksvych M, Fennessey CM, Cromer D, Reid C, Trubey CM, Lifson JD, Keele BF, Davenport MP. 2019. Predictors of SIV reservoirs following antiretroviral treatment interruption. Elife 8.

55. Bhand AM, Simonetti FR, Kumar MR, Fray EJ, Brunner KM, Timmons AE, Tai KY, Jenike KM, Antar AAR, Liu PT, Ho YC, Raugi DN, Seydi M, Gottlieb GS, Okoye AA, Del Prete QG, Picker LJ, Mankowski JL, Lifson JD, Siliacano JD, Laird GM, Barouch DH, Clements JE, Siliciano RF. 2019. The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections. Cell Host Microbe 26:73-85 e4.

56. Moir S, Fauci AS. 2017. B-cell responses to HIV infection. Immunol Rev 275:33-48.
HIV DNA: a global marker of HIV persistence.

Cell Host, Fromentin R, Richard J, Porichis F, Charlebois R, Massanella M, Brassard N, Alsahafi N, Delgado GG, Routy JP, Walker BD, Finzi A, Chomont N, Kaufmann DE. 2016. Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. Cell Host Microbe 20:368-380.

Provirial HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 18:1951-3.

Pasternak AO, DeMaster LK, Kootstra NA, Reiss P, O'Doherty U, Berkhout B. 2016. Minor Contribution of Chimeric Host-HIV Readthrough Transcripts to the Level of HIV Cell-Associated gag RNA. J Virol 90:1148-51.

Baxter AE, Niessl J, Fromentin R, Richard J, Porichis F, Charlebois R, Massanella M, Brassard N, Alsahafi N, Delgado GG, Routy JP, Walker BD, Finzi A, Chomont N, Kaufmann DE. 2016. Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. Cell Host Microbe 20:368-380.

Yerly S, Gunthard HF, Fagard C, Joos B, Perneger TV, Hirschel B, Perrin L, Swiss HIVCS. 2004. Proviral HIV-DNA predicts viral rebound and viral setpoint after structured treatment interruptions. AIDS 18:1951-3.
Lederman MM, Haddad EK. 2013. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat Med 19:494-9.

Yamamoto T, Lynch RM, Gautam R, Matus-Nicodemos R, Schmidt SD, Boswell KL, Darko S, Wong P, Sheng Z, Petrovas C, McDermott AB, Seder RA, Keele BF, Shapiro L, Douek DC, Nishimura Y, Mascola JR, Martin MA, Koup RA. 2015. Quality and quantity of TFH cells are critical for broad antibody development in SHIVAD8 infection. Sci Transl Med 7:298ra120.

Xu H, Wang X, Lackner AA, Veazey RS. 2014. PD-1(HIGH) Follicular CD4 T Helper Cell Subsets Residing in Lymph Node Germinal Centers Correlate with B Cell Maturation and IgG Production in Rhesus Macaques. Front Immunol 5:85.

Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, De Leval L, Graziosi C, Pantaleo G. 2013. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 210:143-56.

Wang X, Xu H. 2018. Potential Epigenetic Regulation in the Germinal Center Reaction of Lymphoid Tissues in HIV/SIV Infection. Front Immunol 9:159.

Wargo AR, Kurath G. 2012. Viral fitness: definitions, measurement, and current insights. Curr Opin Virol 2:538-45.

Domingo E, Sheldon J, Perales C. 2012. Viral quasispecies evolution. Microbiol Mol Biol Rev 76:159-216.

Figure legends

Figure 1. Plasma viral load and immunological events in SHIV.C.CH848-inoculated rhesus macaques on antiretroviral therapy. Plasma viral load in SHIV-infected macaques subsequently treated with anti-HIV drugs for 6 months, initiated 5 months post SHIV infection (n=5, a) compared to untreated controls (n=5, b); (c-f) Changes in peripheral CD20+ B and CD4+ T cells, rectal CD4+ T cells and T follicular helper cells in untreated and treated animal groups; (g) PD-1 expression on peripheral CD8+ T cells. Note viral rebound was observed in 4 of 5 of animals after cART interruption. (h) SHIV.C.CH848 gag-specific cytokine (TNF-α and IFN-γ) responses of peripheral CD8+ T cells in two animal cohorts with (red) or without ART (black) at 44 weeks post SHIV infection. Error bars indicate means +/-SEM. Paired t tests were used to compare ART-treated with untreated groups. *, p<0.01.

Figure 2. Dynamics of cell-associated SHIV RNA and DNA in CD4+ T cells from PBMCs and lymph nodes of SHIV.C.CH848-infected macaques on antiretroviral therapy, compared with CD4 negative cells. Longitudinal analysis of unspliced SHIV RNA (US SHIV RNA) (a and b), total SHIV DNA (c and d), or integrated proviral SHIV DNA (e and f) in CD4+ T cells and CD4 negative cell populations derived from
peripheral blood and lymph nodes of SHIV-infected macaques with or without cART. Note that proviral DNA was detectable even under cART, especially in purified CD4+ T cells. Cell-associated SHIV RNA and DNA are expressed as copies per 1 million cells. The dotted line represents the limit of detection (LOD) as calculated in Methods. Error bars indicate means +/- SEM. *p<0.01, determined by two-tailed paired t test in either blood or lymph node tissue of treated and untreated animals. #, p<0.01, compared between at pre- (month 5 p.i.) and after treatment in both tissues at different time points.

**Figure 3.** Cell-associated SHIV RNA and DNA in total PBMC and rectal lymphocytes in SHIV.C.CH848-infected rhesus macaques on antiretroviral therapy. (a-c) Changes in levels of US SHIV RNA, total SHIV DNA, or proviral SHIV DNA in rectal lymphocytes; (d-f) Levels of US SHIV RNA, total SHIV DNA, or proviral SHIV DNA in PBMCs at pre-treatment (month 5 p.i.), cART-treated and untreated groups at 6 months. Error bars indicate means +/- SEM. *, p<0.01, Paired t test was used to compare groups. #, p<0.01, comparison between pre-treatment (month 5 p.i.) and after treatment in rectal tissue at different time points. ##, p<0.05, comparison with pre-treatment or untreated controls in blood.

**Figure 4.** Viral Env evolution in SHIV.C.CH848-infected macaques. Amino acid highlighter plots showing single genome env sequences from SHIV.C.CH848-infected RM at 5 months post-infection. Non-synonymous substitutions compared to the TF sequence are indicated by a red line and deletions are shown as a black line. Each horizontal line shows one single genome sequence. 2 common sites of selection pressure (Env residues 3/4 and 195) were identified in infected animals.

**Table 1.** Neutralizing antibody responses in SHIV.C.CH848-infected macaques. Plasma from SHIV.C.CH848-infected RM at 5, 15 months and 2 years post infection were tested against a panel of autologous and heterogeneous viruses in TZM-bl cells. Colors indicate potency: 50–99, green; 100–999, yellow; ≥1,000, red.
Figure 1

(a) Viral load in plasma (Copies/ml) over weeks post SHIV-CH848 infection.

(b) cART treatment effect on viral load in plasma.

(c) Percentage of CD20+ B cells in blood over days post SHIV-CH848 infection.

(d) cART treatment effect on CD4+ T cells in blood.

(e) Percentage of CD4+ T cells in rectum over days post SHIV-CH848 infection.

(f) cART treatment effect on GC Tfh cells in LNs.

(g) Percentage of PD-1 on CD8+ T cells over weeks post SHIV-CH848 infection.

(h) Percent cytokine-producing peripheral CD8+ T cells.
Figure 2

**Proviral SHIV DNA in CD4+ T cells**

- **a** Lymph node
- **b** Blood
- **c** cART
- **d** Lymph node
- **e** Blood
- **f** cART

**US SHIV RNA in CD4+ T cells**

- **a** Lymph node
- **b** Blood
- **c** cART
- **d** Lymph node
- **e** Blood
- **f** cART

**Total SHIV DNA in CD4+ T cells**

- **a** Lymph node
- **b** Blood
- **c** cART
- **d** Lymph node
- **e** Blood
- **f** cART

**US SHIV RNA in CD4-NEG cells**

- **a** Lymph node
- **b** Blood
- **c** cART
- **d** Lymph node
- **e** Blood
- **f** cART

**Weeks post SHIV-CH848 infection**
Figure 3

(a) US SHIV RNA in PBMC LNs (Copies/10^6 cells) over weeks post SHIV-CH848 infection.
(b) Total SHIV DNA in PBMC LNs (Copies/10^6 cells) over weeks post SHIV-CH848 infection.
(c) Proviral SHIV DNA in PBMC LNs (Copies/10^6 cells) over weeks post SHIV-CH848 infection.
(d) US SHIV RNA in PBMC and LNs (Copies/10^6 cells).
(e) Total SHIV DNA in PBMC and LNs (Copies/10^6 cells).
(f) Proviral SHIV DNA in PBMC and LNs (Copies/10^6 cells).
1. V3M/M4T or R  
2. P195S or L  
3. S375H
Table 1. Plasma neutralization ID50 titers of SHIV.C.CH848 infected rhesus macaques

| ID     | Plasma CH848 | CH848 Du156.12 | ZM109.4 | Q23.17 | BG505 | Yu2 | JR-FL | AD17 |
|--------|--------------|----------------|---------|---------|-------|-----|-------|------|
| #1 (cART) | <20 | <25 | 27 | ND* | ND | ND | ND | ND | ND | ND | ND | ND |
| #2 (cART) | 57 | 92 | 214 | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| #3 (cART) | 96 | 272 | 316 | <25 | <25 | <25 | <25 | <25 | <25 | <25 | <25 | <25 |
| #4 (cART) | 34 | 508 | 1,330 | <25 | 28 | <25 | <25 | <25 | <25 | <25 | <25 | <25 |
| #5 (cART) | 37 | 100 | 472 | <25 | <25 | <25 | <25 | <25 | <25 | <25 | <25 | <25 |
| #6 | 342 | 215 | 113 | <25 | <25 | <25 | <25 | <25 | <25 | <25 | <25 | <25 |
| #7 | 149 | 554 | 392 | <25 | 51 | 336 | 26 | <25 | 26 | <25 | <25 | <25 |
| #8 | 21 | 183 | 347 | <25 | <25 | 36 | <25 | <25 | <25 | <25 | <25 | <25 |
| #9 | 22 | 267 | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND |
| #10 | 48 | 369 | 630 | <25 | <25 | <25 | <25 | <25 | <25 | <25 | <25 | <25 |

ND*, Not detected.